Literature DB >> 16156324

Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study.

Scott Modena1, Dilip Bearelly, Kenneth Swartz, Frank K Friedenberg.   

Abstract

OBJECTIVES: Clostridium difficile is the most common cause of infectious nosocomial diarrhea and can be found in up to 30% of asymptomatic hospitalized patients. Our primary aim was to compare the clinical characteristics of hospitalized patients who received antibiotics and developed C. difficile-associated diarrhea (CDAD) with those of hospitalized patients who received antibiotics and did not develop the disease.
DESIGN: Case-control study comprising inpatients at a single institution. PATIENTS: Case-patients were defined as patients who had diarrhea and tested positive for C. difficile. Control-patients (matched 4:1 to case-patients) were defined as patients who received antibiotics for at least 5 days and did not develop CDAD.
RESULTS: On univariate analysis, nine variables were associated with CDAD. Only three of the variables, need for intensive care, length of stay, and macrolide antibiotic use, were found to be significant (P < .05) on logistic regression analysis. The odds ratios for status as a CDAD case were 3.68 (CI95, 1.44 to 9.40) for stay in the intensive care unit and 1.03 (CI95, 1.02 to 1.05) for each day of hospital stay. Receipt of macrolide antibiotics reduced risk significantly; the odds ratio was 0.23 (CI95, 0.19 to 0.87).
CONCLUSIONS: We identified need for intensive care and length of stay as important risk factors for the development of CDAD. We also identified macrolide antibiotic use as protective against its development. Patients receiving intensive care may represent a population to study for targeted prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16156324     DOI: 10.1086/502603

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  13 in total

Review 1.  Clostridium difficile in the ICU: the struggle continues.

Authors:  Linda D Bobo; Erik R Dubberke; Marin Kollef
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

2.  Clostridium difficile-associated disease acquired in the neurocritical care unit.

Authors:  S A Musa; H Robertshaw; S J Thomson; M L Cowan; T M Rahman
Journal:  Neurocrit Care       Date:  2010-08       Impact factor: 3.210

3.  Association between Clostridium difficile infection and antimicrobial usage in a large group of English hospitals.

Authors:  Joao B Pereira; Tracey M Farragher; Mary P Tully; Jonathan Jonathan Cooke
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

Review 4.  Clostridium difficile infection: clinical spectrum and approach to management.

Authors:  Chetana Vaishnavi
Journal:  Indian J Gastroenterol       Date:  2011-12-20

5.  Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis.

Authors:  Tadayuki Oshima; Liping Wu; Min Li; Hirokazu Fukui; Jiro Watari; Hiroto Miwa
Journal:  J Gastroenterol       Date:  2017-07-25       Impact factor: 7.527

6.  Clostridium difficile in urology.

Authors:  M Hossain; T J Crook; S R Keoghane
Journal:  Ann R Coll Surg Engl       Date:  2008-01       Impact factor: 1.891

7.  Asymptomatic carriage of Clostridium difficile in an Irish continuing care institution for the elderly: prevalence and characteristics.

Authors:  J Ryan; C Murphy; C Twomey; R Paul Ross; M C Rea; J MacSharry; B Sheil; F Shanahan
Journal:  Ir J Med Sci       Date:  2009-06-04       Impact factor: 1.568

8.  Assessing the Risk of Hospital-Acquired Clostridium Difficile Infection With Proton Pump Inhibitor Use: A Meta-Analysis.

Authors:  Vanessa Arriola; Jessica Tischendorf; Jackson Musuuza; Anna Barker; Jeffrey W Rozelle; Nasia Safdar
Journal:  Infect Control Hosp Epidemiol       Date:  2016-09-28       Impact factor: 3.254

9.  In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.

Authors:  Manoj Kumar; Tarun Mathur; Tarani K Barman; G Ramkumar; Ashish Bhati; Gunjan Shukla; Vandana Kalia; Manisha Pandya; V Samuel Raj; Dilip J Upadhyay; Chetana Vaishnavi; Anjan Chakrabarti; Biswajit Das; Pradip K Bhatnagar
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

Review 10.  The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis.

Authors:  Imad M Tleyjeh; Aref Bin Abdulhak; Aref A Bin Abdulhak; Muhammad Riaz; Musa A Garbati; Mohamad Al-Tannir; Faisal A Alasmari; Mushabab Alghamdi; Abdur Rahman Khan; Patricia J Erwin; Alex J Sutton; Larry M Baddour
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.